FMP

FMP

Enter

Exelixis Initiated at Buy with Promising Growth Outlook

- (Last modified: Dec 24, 2024 1:15 AM)

twitterlinkedinfacebook
blog post cover photo

Image credit: FMP

Brookline Capital Markets analysts initiated coverage of Exelixis (NASDAQ:EXEL) with a Buy rating, highlighting the biotech company’s strong commercial presence and growth potential across its drug portfolio and pipeline. The firm sees significant upside, projecting Exelixis could reach a valuation of $40 per share within the next 12 to 18 months.

Exelixis, a commercial-stage biotechnology company, is expected to continue expanding its key therapies, Cabometyx and Cometriq, while its partner Genentech advances Cotellic. The company’s robust early-stage pipeline also holds potential for future growth. The analysts estimate that Exelixis’ total revenue could grow at a compound annual growth rate (CAGR) of 15% over the next 7 to 10 years, reaching $7.1 billion by 2033.

Key drivers of this growth include additional indications for Cabometyx and the anticipated commercialization of a new pipeline product within the coming years. The analysts expect total product sales to grow to $6.7 billion by 2033, assuming successful execution. However, as with all development-stage biotech companies, these estimates carry inherent risks related to clinical development and market adoption.

Other Blogs

May 14, 2024 11:41 AM - Sanzhi Kobzhan

The easiest way to calculate stock’s target price and why the target price is important.

A stock's target price, also known as its fair value, is an indication of what a share can cost based on the company’s forecasted financial statements. It is important to know a stock's fair value to find undervalued stocks with great growth potential. Let's consider how investment analysts calculat...

blog post title

May 24, 2024 9:30 AM - Rajnish Katharotiya

How to Access and Analyze Earnings Call Transcripts

Earnings call transcripts are invaluable resources for investors, analysts, and financial enthusiasts. They provide insights into a company's performance, strategy, and future outlook, making them essential for making informed investment decisions. With Financial Modeling Prep, Earnings Call Transcr...

blog post title

May 27, 2024 3:30 PM - Rajnish Katharotiya

The best 5 GPU stocks other than NVDA

In the ever-evolving world of technology, certain sectors have consistently demonstrated exceptional growth and innovation. The graphics processing units (GPUs) industry is one such sector, offering investors a golden opportunity for potentially high returns. In this blog, we'll delve into why inves...

blog post title
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep